Zoetis (ZTS) Cash from Financing Activities (2012 - 2026)
Zoetis' (ZTS) quarterly Cash from Financing Activities came in at -$813.0 million in Q2 2026, down 44.15% year-over-year from -$1.5 billion in Q2 2025, and up 3.21% quarter-over-quarter from -$840.0 million in Q1 2026.
Analysis
Zoetis (ZTS) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Cash from Financing Activities for 15 consecutive years, with -$813.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Financing Activities fell 44.15% year-over-year to -$813.0 million in Q2 2026; TTM through Jun 2026 was -$2.3 billion, a 12.7% increase from a year earlier, with the FY2025 full-year figure at -$1.9 billion, up 29.7% from the prior year.
- Cash from Financing Activities was -$813.0 million for Q2 2026 at Zoetis, up from -$840.0 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $780.0 million in Q4 2022 and troughed at -$1.8 billion in Q1 2023.
- A 5-year average of -$566.4 million and a median of -$554.5 million in 2022 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities jumped 348.41% in 2022 and slumped 230.64% in 2023, its largest moves.
- Over 5 years, Cash from Financing Activities stood at $780.0 million in 2022, then sank by 150.9% to -$397.0 million in 2023, then slumped by 87.66% to -$745.0 million in 2024, then jumped by 33.56% to -$495.0 million in 2025, then plunged by 64.24% to -$813.0 million in 2026.
- The last three Cash from Financing Activities figures came in at -$813.0 million (Q2 2026), -$840.0 million (Q1 2026), and -$495.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.69 Bn | 40.49 Bn | 779.09 Mn | -325.19 Mn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn | -813.00 Mn |
| 3 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | -74.00 Mn |
| 4 | Phibro Animal Health | 1.49 Bn | 1.41 Bn | 134.40 Mn | -1.62 Mn |
| 5 | Immucell | 90.19 Mn | 81.33 Mn | 2.44 Mn | - |
| 6 | Zhengye Biotechnology Holding | 76.23 Mn | 69.14 Mn | - | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | 105,646.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -813.00 Mn |
| Mar 31, 2026 | -840.00 Mn |
| Dec 31, 2025 | -495.00 Mn |
| Sep 30, 2025 | -134.00 Mn |
| Jun 30, 2025 | -564.00 Mn |
| Mar 31, 2025 | -677.00 Mn |
| Dec 31, 2024 | -745.00 Mn |
| Sep 30, 2024 | -628.00 Mn |
| Jun 30, 2024 | -763.00 Mn |
| Mar 31, 2024 | -524.00 Mn |
| Dec 31, 2023 | -397.00 Mn |
| Sep 30, 2023 | -416.00 Mn |
| Jun 30, 2023 | -494.00 Mn |
| Mar 31, 2023 | -1.80 Bn |
| Dec 31, 2022 | 780.00 Mn |
| Sep 30, 2022 | -529.00 Mn |
| Jun 30, 2022 | -610.00 Mn |
| Mar 31, 2022 | -545.00 Mn |
| Dec 31, 2021 | -314.00 Mn |
| Sep 30, 2021 | -919.00 Mn |